Under CEO Dave Ricks, Eli Lilly & Co. has seen a dramatic turnaround, becoming the world's most valuable healthcare corporation with a market capitalization of $1 trillion. This success is primarily driven by its blockbuster diabetes drug Mounjaro and obesity drug Zepbound. These drugs accounted for roughly half of Lilly's revenue last year, transforming the company's financial standing and public image, with patients sending testimonials of significant weight loss.
To counter the pharmaceutical industry's inherent boom-and-bust cycle, where generic versions erode sales after patent expiry, Lilly is actively diversifying its pipeline. The company has about a decade of patent protection left on Mounjaro and Zepbound, but competition is already intensifying from companies like Novo Nordisk and over 120 other firms developing similar drugs. Lilly is also facing new threats from the rapid rise of AI in drug discovery.
In response, Lilly has embarked on a record spending spree, announcing acquisitions worth over $20 billion so far in 2026. This includes significant deals like up to $7.8 billion for Centessa Pharmaceuticals Plc, up to $7 billion for Kelonia Therapeutics, and $3.8 billion for three vaccine developers. The company is strategically investing in earlier-stage medicines and platforms, including genetic medicines and AI technologies, with collaborations like a $2.25 billion deal with Profluent Inc. and a $2.75 billion agreement with Insilico Medicine Cayman TopCo. This aggressive reinvestment of obesity cash flows aims to enhance its pipeline and prevent a repeat of past challenges, such as the downturn after the patent loss of Prozac in the early 2000s.
Lilly's investment push is supported by strong earnings, with profits more than doubling in Q1, and cash and highly liquid assets reaching $7.3 billion by the end of 2025. The company is actively building an AI-led drug discovery network, described by CEO Ricks as an "App Store" for scientists, and has signed about 20 deals to license AI technology. Its R&D budget is expected to be in the high teens of billions of dollars this year, compared to $13 billion in 2025. This proactive strategy is designed to ensure sustained growth beyond its current top-selling drugs.
